Article Text

Download PDFPDF
Hepatocellular adenomas: one step beyond
  1. Jean-Yves Scoazec1,2
  1. 1 AMMICa, CNRS-UMS 3655 and INSERM-US23, Gustave Roussy, Villejuif, France
  2. 2 Department of Pathology and Translational Research, Gustave Roussy Cancer Centre, Villejuif, France
  1. Correspondence to Professor Jean-Yves Scoazec, AMMICa, CNRS-UMS 3655 and INSERM-US23, Gustave Roussy, Villejuif 94805, France; Jean-yves.SCOAZEC{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In Gut, Longerich et al describe the identification of a new gene, RSPO2, involved in the pathogenesis of hepatocellular adenomas (HCA) and of a small fraction of hepatocellular carcinomas (HCC), through the activation of the Wnt/beta-catenin pathway, already known to be involved in the pathogenesis of a significant proportion of liver tumours.1 These results reduce the percentage of so-called ‘unclassified’ HCA, underline the tight relationship of some HCA with HCC and add another piece to the puzzle of the extraordinary clinical and biological diversity of HCA. This prompts several comments, mainly about the ‘HCA story’, but also about general tumour biology.

The ‘HCA story’ is a paradigm of how the better knowledge of a tumour group might form the basis of a better tumour classification and how a better tumour classification might result in an improved management of the patients. At the end of the previous century, HCA were viewed as rare benign liver tumours, occurring mainly in young females in the context of oral contraception.2 Their management was simple: when feasible, surgical resection was performed in all cases in order to prevent sometimes severe complications, such as rupture or bleeding. The risk of malignant transformation was a matter of debate. With the new millennium, started a series of in-depth molecular investigations which definitively changed our understanding of this tumour group, with major consequences on their clinical management and their understanding.3 From what was previously seen as a homogeneous entity, rapidly emerged a much …

View Full Text


  • Contributors Full authorship.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Patient consent for publication Not required.

Linked Articles

  • Hepatology
    Thomas Longerich Volker Endris Olaf Neumann Eugen Rempel Martina Kirchner Zahra Abadi Sebastian Uhrig Mark Kriegsmann Karl Heinz Weiss Kai Breuhahn Arianeb Mehrabi Tim Frederik Weber Ludwig Wilkens Beate K Straub Andreas Rosenwald Falko Schulze Benedikt Brors Stefan Froehling Rossella Pellegrino Jan Budczies Peter Schirmacher Albrecht Stenzinger